The SGLT2 inhibitor canagliflozin is associated with a reduction in non-ST elevation MI (non-STEMI) but not ST elevation MI (STEMI) in patients with type 2 diabetes and high cardiovascular risk, Australian research shows. A post hoc analysis of data from the CANVAS program and CREDENCE trial found 599 (4.1%) of 14,543 patients experienced an MI. ...
Differential effect of SGLT2 inhibitor on STEMI and non-STEMI in T2D warrants further study
By Mardi Chapman
9 Apr 2021